Clinical trials: Active Systemic Lupus Erythematosus
SLE (Systemic Lupus)
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity
Assessment of CXCL5 biomarker in Serum of patients of SLE in comparison to healthy patients and its correlation with disease activity
- Trial name
- NCT06610409
- Testing
- blood sampling
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Active Systemic Lupus Erythematosus
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
- Trial name
- NCT04931563
- Testing
- Anifrolumab
- Where
- 65 sites in China, Hong Kong and 4 more
- Volunteers
- 277 people
- Sponsor
- AstraZeneca
Arthritis, Gout
Phone-Based Based Walk With Ease Program for Adults With Arthritis
The objective of this study is to examine the short-term (6-weeks and 6 months) and long-term (1 year) effects of a phone-based version of Walk With Ease intervention.
- Conditions
- Arthritis, Gout, Fibromyalgia, Rheumatoid Arthritis
- Trial name
- NCT05289544
- Testing
- Phone-Based Walk With Ease
- Where
- United States
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Refractory Active Systemic Lupus Erythematosus
A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus
This study aimed to observe the safety and tolerability of SYS6020 in adult participants with refractory active systemic lupus erythematosus, determine the recommended dose (RD) that may be explored for subsequent studies, and…
- Trial name
- NCT06694298
- Testing
- SYS6020
- Volunteers
- 50 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Systemic Lupus Erythematosus
Regulatory BCells in Systemic Lupus Erythematosus
Systemic lupus erythematosus , the archetypal multisystem autoimmune disease, presents many diagnostic and management challenges.
- Trial name
- NCT03178721
- Testing
- blood sample
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Multicomponent Strategy to Implement a Clinical Practice Guideline and Improve Health Outcomes in People With SLE
Principal objective: To produce scientific knowledge on the effectiveness and cost-effectiveness of a multicomponent intervention for knowledge transfer and implementing a Clinical Practice Guideline (CPG) for Systemic Lupus…
- Trial name
- NCT03537638
- Testing
- Multicomponent intervention
- Where
- Spain
- Volunteers
- 237 people
- Sponsor
- Servicio Canario de Salud
Lupus Nephritis
Urinary G3BP as a Novel Biomarker in Lupus Nephritis
Estimation of urinary Galectin-3 binding protein (u-Gal-3BP) in patients with systemic lupus erythematosus with and without lupus nephritis and in glomerulonephritis for other kidney diseases, Find the relation of urinary…
- Trial name
- NCT06520670
- Testing
- Urinary galectin-3 binding protein
- Volunteers
- 70 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and…
- Trial name
- NCT06570798
- Testing
- Inebilizumab, Blinatumomab
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 220 people
- Sponsor
- Amgen
Lupus Erythematosus, Systemic
A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
Primary objective: To assess the efficacy and safety of different dose regimens of ALX-0061 administered subcutaneously (s.c.) to subjects with moderate to severe active, seropositive systemic lupus erythematosus (SLE) compared…
- Trial name
- NCT02437890
- Testing
- ALX-0061
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 312 people
- Sponsor
- Ablynx, a Sanofi company
Lupus
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic lupus erythematosus in male and female adults.
- Trial name
- NCT02265744
- Testing
- BMS-931699
- Where
- 121 sites in United States, Argentina and 21 more
- Volunteers
- 730 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus (SLE)
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus
- Trial name
- NCT07215663
- Testing
- Cizutamig
- Where
- 17 sites in China
- Volunteers
- 47 people
- Sponsor
- Candid Therapeutics
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid
Autologous Polyclonal Tregs for Lupus
The primary purpose of this Phase 1 study is to evaluate the safety, tolerability, and effect of 3 different doses of Treg therapy in adults with skin (cutaneous) involvement of their lupus.
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
- Trial name
- NCT02428309
- Testing
- Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus
Approximately 225 patients meeting study entry requirements will be enrolled and randomized (2:1, active versus placebo superimposed on background treatment) to R788 or placebo.
- Trial name
- SOLEIL (NCT00752999)
- Testing
- Fostamatinib Disodium (R935788)
- Sponsor
- Rigel Pharmaceuticals
Immune System Diseases, Autoimmune Diseases
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
To evaluate safety, tolerability pharmacokinetics and immunogenicity of CDP7657.
- Conditions
- Immune System Diseases, Autoimmune Diseases, Lupus Erythematosus, Systemic, Skin and Connective Tissue Diseases
- Trial name
- NCT01764594
- Testing
- CDP7657
- Where
- 21 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 24 people
- Sponsor
- UCB Pharma
Systemic Lupus Erythematosus
A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs.
- Trial name
- NCT05638802
- Testing
- DS-7011a
- Where
- 20 sites in United States, China and 2 more
- Volunteers
- 26 people
- Sponsor
- Daiichi Sankyo
Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus
This study is evaluating whether afimetoran, an investigational oral medicine that blocks toll-like receptors 7 and 8 (TLR7/TLR8), can improve skin disease in adults with active cutaneous lupus erythematosus (CLE), with or…
- Trial name
- DISCOVERY (NCT07881120)
- Testing
- Afimetoran
- Where
- 3 sites in United States
- Volunteers
- 390 people
- Sponsor
- Beeline Medicines Corporation
Systemic Lupus Erythematosus
A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus
The goal of this clinical trial is to learn if sulfasalazine is safe and feasible in the treatment of active lupus erythematosus (SLE).
- Trial name
- NCT06360068
- Testing
- Sulfasalazine Tablets
- Volunteers
- 20 people
- Sponsor
- Qiong Fu
Systemic Lupus Erythematosus, Lupus Nephritis
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Trial name
- NCT06121297
- Testing
- CABA-201
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 28 people
- Sponsor
- Cabaletta Bio
Lupus Nephritis (LN)
Dapagliflozin in Active Lupus Nephritis
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure.
- Trial name
- Dapa-Active LN (NCT07323524)
- Testing
- Dapagliflozin (10Mg Tab) along with standard medical therapy
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Brigham and Women's Hospital
SLE
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.
- Trial name
- LUMUS (NCT05966480)
- Testing
- Envudeucitinib
- Where
- 169 sites in United States, Argentina and 19 more
- Volunteers
- 408 people
- Sponsor
- Alumis Inc